Adicet Bio, Inc. (0HX7.L)
USD 0.92
(-3.81%)
USD 0.92
(-3.81%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -136.53 Million USD | -87.26% |
| 2022 | -64.7 Million USD | -17.74% |
| 2021 | -57.88 Million USD | -90.33% |
| 2020 | -37.4 Million USD | 0.03% |
| 2019 | -30.15 Million USD | 23.91% |
| 2018 | -37.5 Million USD | -109.91% |
| 2017 | -18.87 Million USD | -1887600.0% |
| 2016 | -1000.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -31.24 Million USD | -6.94% |
| 2024 Q1 | -29.22 Million USD | 2.2% |
| 2023 Q1 | -31.5 Million USD | -5.78% |
| 2023 FY | - USD | -87.26% |
| 2023 Q4 | -29.87 Million USD | 1.89% |
| 2023 Q3 | -30.45 Million USD | 6.61% |
| 2023 Q2 | -32.6 Million USD | -3.49% |
| 2022 FY | - USD | -17.74% |
| 2022 Q4 | -29.78 Million USD | -36.51% |
| 2022 Q2 | -21.64 Million USD | -479.5% |
| 2022 Q1 | 5.7 Million USD | 138.41% |
| 2022 Q3 | -21.81 Million USD | -0.81% |
| 2021 FY | - USD | -90.33% |
| 2021 Q2 | -9.67 Million USD | 52.43% |
| 2021 Q4 | -14.84 Million USD | -18.81% |
| 2021 Q1 | -20.34 Million USD | -1226.08% |
| 2021 Q3 | -12.49 Million USD | -29.15% |
| 2020 Q2 | -8.31 Million USD | -14.81% |
| 2020 Q1 | -7.24 Million USD | -4.97% |
| 2020 FY | - USD | 0.03% |
| 2020 Q4 | -1.53 Million USD | 88.53% |
| 2020 Q3 | -13.37 Million USD | -60.76% |
| 2019 Q3 | -14.91 Million USD | -247.66% |
| 2019 FY | - USD | 23.91% |
| 2019 Q1 | -4.04 Million USD | 0.0% |
| 2019 Q2 | -4.28 Million USD | -5.93% |
| 2019 Q4 | -6.9 Million USD | 53.72% |
| 2018 FY | - USD | -109.91% |
| 2017 FY | - USD | -1887600.0% |
| 2016 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 16.296% |
| Dynavax Technologies Corporation | 9.66 Million USD | 1512.528% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 238.95% |
| Perrigo Company plc | 646.2 Million USD | 121.129% |
| Illumina, Inc. | -608 Million USD | 77.544% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 101.264% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 69.592% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 98.789% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 104.193% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -31.547% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 102.934% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -266.212% |
| Waters Corporation | 1.02 Billion USD | 113.356% |
| Biogen Inc. | 2.37 Billion USD | 105.744% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -56.17% |
| Evolus, Inc. | -41.81 Million USD | -226.561% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -16.052% |
| bluebird bio, Inc. | -167.16 Million USD | 18.321% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 9.042% |
| FibroGen, Inc. | -261.4 Million USD | 47.769% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 108.142% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -207.257% |
| Homology Medicines, Inc. | -47.75 Million USD | -185.901% |
| Geron Corporation | -174.78 Million USD | 21.883% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 40.148% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -48.28% |
| Myriad Genetics, Inc. | -67.8 Million USD | -101.379% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -35.415% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 73.034% |
| Zoetis Inc. | 3.68 Billion USD | 103.705% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -169.981% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 111.729% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 144.003% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 102.965% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -278.402% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 40.64% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 48.67% |
| Verastem, Inc. | -83.16 Million USD | -64.172% |
| Nektar Therapeutics | -243.1 Million USD | 43.837% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 39.315% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -55.18% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 68.913% |
| OPKO Health, Inc. | -65.51 Million USD | -108.399% |
| Exelixis, Inc. | 196.6 Million USD | 169.447% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 132.813% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 226.043% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -144.879% |
| uniQure N.V. | -253.1 Million USD | 46.055% |
| Imunon, Inc. | -20.78 Million USD | -556.978% |
| Blueprint Medicines Corporation | -474.61 Million USD | 71.232% |
| Insmed Incorporated | -654.73 Million USD | 79.147% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 130.21% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 60.478% |
| TG Therapeutics, Inc. | 26.1 Million USD | 623.123% |
| Incyte Corporation | 919.42 Million USD | 114.85% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 72.979% |